This invention relates to a medical device and procedure.
Female sterilization typically involves occluding the fallopian tubes to prevent sperm access to an egg within a female's fallopian tube. One conventional female sterilization procedure is laparoscopic tubal occlusion. In this procedure, an incision is made in the abdominal wall to provide access to the fallopian tubes. The tubes are surgically occluded with the aid of a laparoscope, for example, using bipolar or monopolar coagulation. Laparoscopic tubal occlusion is invasive and requires multiple incisions and passing of several instruments and a gaseous distension medium into the patient's abdomen. Thermal and mechanical injury to the surrounding tissues and organs has been reported.
Minimally invasive transcervical approaches to female sterilization have been used more recently. One such procedure involves placing small, flexible devices into the fallopian tubes; the devices are inserted transcervically into the uterine cavity providing access to the fallopian tubes. The devices are made from polyester fibers and metals and once in place, body tissue grows into the devices and blocks the fallopian tubes. The devices permanently remain in the patient's body, which has raised concerns about the long term effects of the implanted devices as well as restrictions on potential subsequent surgical interventions within the uterus, given the conductive metallic components in the devices.
A monopolar radio frequency technique has been investigated that included passing a small diameter wire (an active electrode) transcervically through the uterine cavity and the tubal ostium to the fallopian tubes. A large, passive electrode is positioned externally. The current path between the two electrodes is not well defined and can lead to inadvertent burns. The technique was not successful and was abandoned. It could manage neither the varying thicknesses of endometrial tissue at the tubal ostium, nor the required tight tolerance on the depth of destruction within the fallopian tubes.
This invention relates to a medical device and procedure. In general, in one aspect, the invention features a method for fallopian tubal occlusion. A tubal occlusion device is inserted into a uterine cavity. The device includes an RF applicator head including an electrode carrier with one or more bipolar electrodes thereon. During insertion, the RF applicator head is in a closed position. The RF applicator head is positioned at a tubal ostium of a fallopian tube such that a distal tip of the RF applicator head advances into the tubal ostium. The RF applicator head is deployed into an open position such that the RF applicator head approximates the shape of the uterine cavity in a region of the tubal ostium. Current is passed through the one or more bipolar electrodes to the tubal ostium to destroy tissue to a known depth, which precipitates a healing response in surrounding tissue that over time scars and occludes the fallopian tube.
Implementations of the invention can include one or more of the following features. Passing current through the one or more bipolar electrodes to the tubal ostium to destroy tissue can include vaporizing endometrium and destroying superficial myometrium. Inserting a tubal occlusion device into a uterine cavity can include inserting the tubal occlusion device with the RF applicator head in a closed position, and before passing current through the one or more bipolar electrodes, deploying the RF applicator head into the open position. Suction can be applied through the electrode carrier to draw the surrounding tissue into contact with the electrodes, and to draw moisture generated during ablation away from the electrodes to substantially prevent the formation of a low impedance liquid layer at the electrodes. Passing current through the one or more bipolar electrodes can include delivering radio frequency energy to the one or more bipolar electrodes.
The method can further include automatically terminating the flow of current into the tissue once ablation has approximately reached a predetermined depth of ablation. Before positioning the RF applicator head at the tubal ostium, the uterine cavity can be insufflated. Insufflation is ceased before passing current through the one or more bipolar electrodes, allowing the uterine cavity to collapse onto the RF applicator head. Deploying the RF applicator head into an open position can include removing a sheath to expose the electrode carrier. The electrode carrier can include a fabric having conductive metallized regions and one or more non-conductive regions formed thereon to create the one or more bipolar electrodes. The method can further include advancing an illuminator and an optical instrument into the uterine cavity. Positioning the RF applicator head at the tubal ostium of a fallopian tube can include using the optical instrument to visualize the tubal ostium.
In general, in another aspect, the invention features a system for fallopian tubal occlusion. The system includes a tubal occlusion device, a source of radio frequency energy, a controller and a vacuum source. The tubal occlusion device has a distal end and a proximal end, the distal end including an electrode carrier with one or more bipolar electrodes thereon. In an open condition the distal end is shaped to approximate a uterine cavity in a region of a tubal ostium of a fallopian tube to be occluded. The source of radio frequency energy is electrically coupled to the one or more bipolar electrodes. The controller is configured to control the delivery of radio frequency energy to the one or more bipolar electrodes such that passing radio frequency energy through the one or more bipolar electrodes to the tubal ostium can be controlled to destroy tissue to a known depth, which precipitates a healing response in surrounding tissue that over time scars and occludes the fallopian tube. The vacuum source is operable to draw the tissue into contact with the one or more bipolar electrodes and to draw moisture generated during delivery of the radio frequency energy to the bipolar electrodes away from the bipolar electrodes. This can substantially eliminate liquid surrounding the bipolar electrodes.
Implementations of the invention can include one or more of the following features. Passing radio frequency energy through the one or more bipolar electrodes to the tubal ostium destroying tissue can include vaporizing endometrium and destroying superficial myometrium. The electrode carrier can include a structural support member within a fabric sheath having conductive metallized regions and having one or more non-conductive regions formed thereon to create the one or more bipolar electrodes. The structural support member can include flexible members movable between a closed condition and the open condition. The system can further include an illumination source electrically coupled to the distal end of the tubal occlusion device to illuminate the uterus, and an optical instrument electrically coupled to the distal end of the tubal occlusion device to provide images of the uterus.
In general, in another aspect, the invention features an apparatus for occluding a fallopian tube. The apparatus includes an elongate member, an electrode carrier and a tube. The elongate member has a distal end, a proximal end and a hollow central interior. The electrode carrier is attached to the distal end of the elongate member and has one or more bipolar electrodes formed thereon. The electrode carrier is operable to couple to a radio frequency energy generator and is movable between a closed position in which the electrode carrier is collapsed for insertion into a uterine cavity, and an open position in which a distal end of the electrode carrier is shaped to fit within a tubal ostium of a fallopian tube. The hollow central interior of the elongate member is operable to couple to a vacuum source and to draw moisture away from the one or more electrodes.
Implementations of the invention can include one or more of the following features. The apparatus can further include an illuminator attached to the distal end of the elongate member and operable to couple to an illumination source, and an optical instrument attached to the distal end of the elongate member and operable couple to an image display device. The electrode carrier can include a structural support member within a fabric sheath having conductive metallized regions and have one or more non-conductive regions formed thereon to create the one or more bipolar electrodes The structural support member can include flexible members movable between a closed condition and the open condition.
Implementations of the invention can realize one or more of the following advantages. The tubal occlusion procedure described is minimally invasive: the tubal occlusion device can be introduced into the patient's uterine cavity transcervically and requires no abdominal incision. The procedure does not leave any foreign objects in the patient's body, minimizing the risk of infection and eliminating the need to restrict subsequent surgical intervention options. The procedure can be performed quickly, the actual duration of ablation being approximately one minute per fallopian tube. Because the RF energy is limited to the region of ablation, there is less risk of damage to other organs during the procedure. The system and procedure automatically compensate for varying endometrial thicknesses, facilitating the proper, contoured depth of tissue destruction in the region of the tubal opening. Further, unlike the technique described above that implanted permanent devices in the fallopian tubes, there is no need to navigate a catheter through the fallopian tubes, which are prone to spasm, inhibiting the placement of permanent devices, making such a procedure difficult to achieve.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
A method and system for occlusion of a female's fallopian tubes is described that provides a minimally invasive alternative for female sterilization. Referring to
Referring to
Referring to
The main body 4 includes a shaft 10. The shaft 10 is an elongate member having a hollow interior. In one embodiment, the shaft 10 is approximately 30 centimeters long and has a cross-sectional diameter of approximately 4 millimeters. Extending through the shaft 10 is a suction/insufflation tube 17 having a plurality of holes 17a formed in its distal end (see
Referring particularly to
Referring to
The RF applicator head 2 can be deployed into the open position shown in
In an alternative embodiment, the tube 17 can be pushed toward the proximal end of the flexible member 19, i.e., toward the RF applicator head 2, thereby moving the tube 17 relative to the shaft 10. The relative movement has the same effect as described above, that is, the flexible member 19 is deformed outwardly, creating a V-shape at the distal end.
In one embodiment, the fabric is formed from a composite yarn with a thermoplastic elastomer (TPE) core and multiple polyfilament nylon bundles wound around the TPE as a cover. The nylon bundles are plated with thin conductive metal layers. Preferably, the nylon is metallized, but not the TPE core. This construction facilitates stretching; the nylon windings open up their coils as the TPE core is elongated, without cracking the metallic layer. The TPE core facilitates recovery from the stretched position, pulling the nylon coils back into their initial configuration.
In an alternative embodiment, the electrode carrier 12 can be a sack formed of a material that is non-conductive, that is permeable to moisture, and that can be compressed to a smaller volume and subsequently released to its natural size upon elimination of compression. Examples of materials for the electrode carrier 12 include foam, cotton, fabric, or cotton-like material, or any other material having the desired characteristics. The electrodes 14 can be attached to the outer surface of the electrode carrier 12, e.g., by deposition or another attachment mechanism. The electrodes 14 can be made of lengths of silver, gold, platinum, or any other conductive material. The electrodes 14 can be formed on the electrode carrier 12 by electron beam deposition, or they can be formed into coiled wires and bonded to the electrode carrier 12 using a flexible adhesive. Other means of attaching the electrodes, such as sewing them onto the surface of the electrode carrier 12, may alternatively be used.
Depth of destruction of the target tissue can be contoured to achieve repeatable, predetermined depths. Variables such as the electrode construction, power applied to the electrodes (power density or power per unit surface area of the electrode), and the tissue impedance at which power is terminated can be used to affect the depth of tissue destruction, as discussed further below.
The spacing between the electrodes (i.e., the distance between the centers of adjacent electrodes) and the widths of the electrodes are selected so that ablation will reach predetermined depths within the tissue, particularly when maximum power is delivered through the electrodes. Maximum power is the level at which low impedance, low voltage ablation can be achieved. For example, referring to
Referring to
The depth of ablation is also effected by the electrode density (i.e., the percentage of the target tissue area which is in contact with active electrode surfaces) and may be regulated by pre-selecting the amount of this active electrode coverage. For example, the depth of ablation is much greater when the active electrode surface covers more than 10% of the target tissue than it is when the active electrode surfaces covers only 1% of the target tissue.
By way of illustration, by using 3-6 mm spacing and an electrode width of approximately 0.5-2.5 mm, delivery of approximately 20-40 watts over a 9-16 cm2 target tissue area will cause ablation to a depth of approximately 5-7 millimeters when the active electrode surface covers more than 10% of the target tissue area. After reaching this ablation depth, the impedance of the tissue will become so great that ablation will self-terminate. By contrast, using the same power, spacing, electrode width, and RF frequency will produce an ablation depth of only 2-3 mm when the active electrode surfaces covers less than 1% of the target tissue area. This can be better understood with reference to
As is apparent from
Examples of electrode widths, having spacings with less than 1% active electrode surface coverage, and their resultant ablation depth, based on an ablation area of 6 cm2 and a power of 20-40 watts, are given on the following table:
Thus it can be seen that the depth of ablation is significantly less when the active electrode surface coverage is decreased.
Referring to
Referring again to
Once the threshold impedance is detected, the controller shuts off the RF energy, preventing excess destruction of tissue. For example, when transmitting RF energy of 5.5 watts per square centimeter of tissue, an impedance of the tissue of 50 ohms can indicate a depth of destruction of approximately 3 to 4 millimeters at the proximal end H and approximately 2.5 millimeters at the distal end I. In an alternative embodiment, the RF generator 16 can be configured such that above the threshold impedance level the RF generator's ability to deliver RF power is greatly reduced, which in effect automatically terminates energy delivery.
Referring again to
During use, the sheath 32 is retracted from the electrode carrier 12, for example, by moving the distal handle member 34 towards the proximal handle member 37 to slide the sheath 32 in the distal direction. Moving the distal handle member 34 toward the proximal handle member 27 can also advance the shaft 10 in the proximal direction. The movement of the shaft 10 relative to the suction/insufflation tube 17 causes the shaft 10 to pull proximally on the flexible member 19. Proximal movement of the flexible member 19 in turn pulls the flexure 22, causing it to move to the opened condition shown in
The amount by which the flexible member 19 is deformed outwardly from the tube 17 can be controlled by manipulating the handle 6 to slide the shaft 10, proximally or distally. The amount by which the shaft 10 is slid relative to the tube 17 controls the shape of the flexible member 19.
As mentioned above, in an alternative embodiment, the handle 6 can be configured so that the tube 17 can be moved distally relative to the shaft 10. Distal movement of the tube 17 in turn deforms the flexible member 19 outwardly. The amount by which the flexible member 19 is deformed outwardly from the tube 17 can be controlled by manipulating the handle 6 to slide the tube 17 proximally or distally, and the amount by which the tube 17 moves relative to the shaft 10 controls the shape of the flexible member 19.
As shown in
One or more additional components can be provided for endoscopic visualization purposes. For example, lumen 42, 44, and 46 may be formed in the walls of the introducer sheath 32 as shown in
Because during use it is most desirable for the electrodes 14 on the surface of the electrode carrier 12 to be held in contact with the interior surface of the uterine cavity 5 and tubal ostia 9, the electrode carrier 12 may have additional components inside it that add structural integrity to the electrode carrying means when it is deployed within the body.
Referring to
The user visualizes the target tubal ostium 9 on the monitor 47 using images provided by the camera 45 (step 62).
Insufflation is ceased and the uterine cavity 5 is allowed to collapse onto the RF applicator head 2 (step 66). Vacuum can be applied to the RF applicator head 2 via the suction/insufflation tube 17 to draw the surrounding tissue into contact with the electrodes 14 (step 67). The RF generator 16 is turned on to provide RF energy to the electrodes 14 (step 68). The RF energy is ceased once the desired amount of tissue has been ablated (step 69). In one implementation, 5.5 watts of RF power is supplied for per square centimeter of electrode surface area until the predetermined impedance threshold is reached, at which point power is terminated.
The uterine cavity 5 can be insufflated a second time, the RF applicator head 2 collapsed into a closed position and the tubal occlusion device 15 rotated approximately 180°. The RF applicator head 2 can then be positioned at the other tubal ostium 9 and the above procedure repeated to ablate tissue at the other tubal ostium 9. The tubal occlusion device 15 is then closed and withdrawn from the patient's body. After ablation, healing and scarring responses of the tissue at the tubal ostia 9 permanently occlude the fallopian tubes 11, without requiring any foreign objects to remain in the female's body and without any incisions into the female's abdomen. The procedure is fast, minimally invasive, and is highly effective at tubal occlusion.
Referring to
The cage 78 can be collapsed into a narrow cylindrical configuration by moving the internal hypotube 74 relative to the external hypotube 72, e.g., by pushing the internal hypotube 74 distally away from the external hypotube 72. In a collapsed state the cage 78 can fit, for example, within the sheath 32 described above, when the RF applicator head 2 is placed in a closed position. Once the sheath 32 is removed and the internal hypotube 74 is moved back into the open position relative to the external hypotube 72, the nature of the material from which the cage 78 is made expands the cage 78 into the desired shape that is depicted. An electrode carrier, such as the electrode carrier 12 made from a metallized fabric described above, can be fitted over the structural body 70, completing the RF applicator head.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Number | Name | Date | Kind |
---|---|---|---|
552832 | Fort | Jan 1896 | A |
725731 | Linn | Apr 1903 | A |
1620929 | Wallerich | Mar 1927 | A |
1827306 | Chapman et al. | Oct 1931 | A |
2190383 | Newman | Feb 1940 | A |
2347195 | Huff | Apr 1944 | A |
2466042 | Reich et al. | Apr 1949 | A |
3228398 | Leonard et al. | Jan 1966 | A |
3324855 | Heimlich | Jun 1967 | A |
3645265 | Majzlin | Feb 1972 | A |
3840016 | Lindemann | Oct 1974 | A |
3845771 | Vise | Nov 1974 | A |
3858586 | Lessen | Jan 1975 | A |
3877464 | Vermes | Apr 1975 | A |
3924628 | Droegemueller et al. | Dec 1975 | A |
3948270 | Hasson | Apr 1976 | A |
3967625 | Yoon | Jul 1976 | A |
3971378 | Krantz | Jul 1976 | A |
4022215 | Benson | May 1977 | A |
4057063 | Gieles et al. | Nov 1977 | A |
4082096 | Benson | Apr 1978 | A |
4158050 | Zipper | Jun 1979 | A |
4185618 | Corey | Jan 1980 | A |
4233025 | Larson et al. | Nov 1980 | A |
4359454 | Hoffman | Nov 1982 | A |
4380238 | Colucci et al. | Apr 1983 | A |
4415288 | Gordon et al. | Nov 1983 | A |
4449528 | Auth et al. | May 1984 | A |
4465072 | Taheri | Aug 1984 | A |
4492231 | Auth | Jan 1985 | A |
4532924 | Auth et al. | Aug 1985 | A |
4568326 | Rangaswamy | Feb 1986 | A |
4582057 | Auth et al. | Apr 1986 | A |
4601698 | Moulding, Jr. | Jul 1986 | A |
4606336 | Zeluff | Aug 1986 | A |
4628924 | Cimber | Dec 1986 | A |
4662383 | Sogawa et al. | May 1987 | A |
4676258 | Inokuchi et al. | Jun 1987 | A |
4682809 | Huss | Jul 1987 | A |
4691703 | Auth et al. | Sep 1987 | A |
4765331 | Petruzzi et al. | Aug 1988 | A |
4788966 | Yoon | Dec 1988 | A |
4832048 | Cohen | May 1989 | A |
4865047 | Chou et al. | Sep 1989 | A |
4869268 | Yoon | Sep 1989 | A |
4946440 | Hall | Aug 1990 | A |
4949718 | Neuwirth et al. | Aug 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4960133 | Hewson | Oct 1990 | A |
4961435 | Kitagawa et al. | Oct 1990 | A |
4979948 | Geddes et al. | Dec 1990 | A |
4981465 | Ballan et al. | Jan 1991 | A |
4983177 | Wolf | Jan 1991 | A |
5026379 | Yoon | Jun 1991 | A |
5047028 | Qian | Sep 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5065751 | Wolf | Nov 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5105808 | Neuwirth et al. | Apr 1992 | A |
5147353 | Everett | Sep 1992 | A |
5159925 | Neuwirth et al. | Nov 1992 | A |
5186181 | Franconi et al. | Feb 1993 | A |
5188122 | Phipps et al. | Feb 1993 | A |
5188602 | Nichols | Feb 1993 | A |
5217473 | Yoon | Jun 1993 | A |
5226908 | Yoon | Jul 1993 | A |
5242437 | Everett et al. | Sep 1993 | A |
5248312 | Langberg | Sep 1993 | A |
5263585 | Lawhon et al. | Nov 1993 | A |
5277201 | Stern | Jan 1994 | A |
5308327 | Heaven et al. | May 1994 | A |
5318532 | Frassica | Jun 1994 | A |
5322507 | Costello et al. | Jun 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5334209 | Yoon | Aug 1994 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5364393 | Auth et al. | Nov 1994 | A |
5370649 | Gardetto et al. | Dec 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5374283 | Flick | Dec 1994 | A |
5380317 | Everett et al. | Jan 1995 | A |
5383917 | Desai et al. | Jan 1995 | A |
5395311 | Andrews | Mar 1995 | A |
5405322 | Lennox et al. | Apr 1995 | A |
5407071 | Lawhon et al. | Apr 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5437629 | Goldrath | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5451204 | Yoon | Sep 1995 | A |
5474089 | Waynant | Dec 1995 | A |
5505730 | Edwards | Apr 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5514091 | Yoon | May 1996 | A |
5562703 | Desai | Oct 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5588961 | Leone et al. | Dec 1996 | A |
5593404 | Costello et al. | Jan 1997 | A |
5609598 | Laufer et al. | Mar 1997 | A |
5613950 | Yoon | Mar 1997 | A |
5626576 | Janssen | May 1997 | A |
5649924 | Everett et al. | Jul 1997 | A |
5656013 | Yoon | Aug 1997 | A |
5667520 | Bonutti | Sep 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5716343 | Kriesel et al. | Feb 1998 | A |
5730136 | Laufer et al. | Mar 1998 | A |
5730725 | Yoon | Mar 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5807389 | Gardetto et al. | Sep 1998 | A |
5810847 | Laufer et al. | Sep 1998 | A |
5827273 | Edwards | Oct 1998 | A |
5843121 | Yoon | Dec 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5871469 | Eggers et al. | Feb 1999 | A |
5879348 | Owens et al. | Mar 1999 | A |
5885601 | Sokal | Mar 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5897551 | Everett et al. | Apr 1999 | A |
5897553 | Mulier et al. | Apr 1999 | A |
5935137 | Saadat et al. | Aug 1999 | A |
5938660 | Swartz et al. | Aug 1999 | A |
5954715 | Harrington et al. | Sep 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
6002968 | Edwards | Dec 1999 | A |
6014589 | Farley et al. | Jan 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6041260 | Stern et al. | Mar 2000 | A |
6042596 | Bonutti | Mar 2000 | A |
6068613 | Kriesel et al. | May 2000 | A |
6068626 | Harrington et al. | May 2000 | A |
6071277 | Farley et al. | Jun 2000 | A |
6077257 | Edwards et al. | Jun 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6135997 | Laufer et al. | Oct 2000 | A |
6139527 | Laufer et al. | Oct 2000 | A |
6152899 | Farley et al. | Nov 2000 | A |
6159207 | Yoon | Dec 2000 | A |
6164280 | Everett et al. | Dec 2000 | A |
6165172 | Farley et al. | Dec 2000 | A |
6179832 | Jones et al. | Jan 2001 | B1 |
6183468 | Swanson | Feb 2001 | B1 |
6200312 | Zikorus et al. | Mar 2001 | B1 |
6231496 | Wilk et al. | May 2001 | B1 |
6231507 | Zikorus et al. | May 2001 | B1 |
6234178 | Goble | May 2001 | B1 |
6237606 | Zikorus et al. | May 2001 | B1 |
6238393 | Mulier et al. | May 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6245090 | Gilson et al. | Jun 2001 | B1 |
6254601 | Burbank et al. | Jul 2001 | B1 |
6258084 | Goldman et al. | Jul 2001 | B1 |
6263248 | Farley et al. | Jul 2001 | B1 |
6277089 | Yoon | Aug 2001 | B1 |
6293942 | Goble et al. | Sep 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6309384 | Harrington et al. | Oct 2001 | B1 |
6315776 | Edwards et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6325798 | Edwards et al. | Dec 2001 | B1 |
6346102 | Harrington et al. | Feb 2002 | B1 |
6352549 | Everett | Mar 2002 | B1 |
6364877 | Goble et al. | Apr 2002 | B1 |
6369465 | Swanson | Apr 2002 | B1 |
6395012 | Yoon et al. | May 2002 | B1 |
6398780 | Farley et al. | Jun 2002 | B1 |
6428537 | Swanson | Aug 2002 | B1 |
6432116 | Callister et al. | Aug 2002 | B1 |
6475213 | Whayne et al. | Nov 2002 | B1 |
6485500 | Kokish et al. | Nov 2002 | B1 |
6508815 | Strul et al. | Jan 2003 | B1 |
6554780 | Sampson et al. | Apr 2003 | B1 |
6587731 | Ingle et al. | Jul 2003 | B1 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6679269 | Swanson | Jan 2004 | B2 |
6712810 | Harrington et al. | Mar 2004 | B2 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6726682 | Harrington et al. | Apr 2004 | B2 |
6743184 | Sampson et al. | Jun 2004 | B2 |
6752803 | Goldman et al. | Jun 2004 | B2 |
6764488 | Burbank et al. | Jul 2004 | B1 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6939348 | Malecki et al. | Sep 2005 | B2 |
20010041900 | Callister et al. | Nov 2001 | A1 |
20020022870 | Truckai et al. | Feb 2002 | A1 |
20020029051 | Callister et al. | Mar 2002 | A1 |
20020072499 | Clagett | Jun 2002 | A1 |
20020072745 | Truckai et al. | Jun 2002 | A1 |
20030093101 | O'Heeron et al. | May 2003 | A1 |
20030130711 | Pearson | Jul 2003 | A1 |
20030199863 | Swanson | Oct 2003 | A1 |
20040054368 | Truckai et al. | Mar 2004 | A1 |
20040118166 | Huang et al. | Jun 2004 | A1 |
20040172051 | Ravikumar | Sep 2004 | A1 |
20040204720 | Harrington et al. | Oct 2004 | A1 |
20040255958 | Harrington et al. | Dec 2004 | A1 |
20050085880 | Truckai et al. | Apr 2005 | A1 |
20050187561 | Lee-Sepsick et al. | Aug 2005 | A1 |
20050217680 | Callister et al. | Oct 2005 | A1 |
20050273094 | Ryan | Dec 2005 | A1 |
Number | Date | Country |
---|---|---|
384246 | Oct 1923 | DE |
22 22 820 | Nov 1973 | DE |
4001086 | Jan 1990 | DE |
0 056 178 | Apr 1981 | EP |
0 584 930 | Jul 1993 | EP |
1 400 182 | Jun 2004 | EP |
774.550 | Sep 1934 | FR |
70.43012 | Jun 1972 | FR |
48-67586 | Sep 1973 | JP |
58-32756 | Feb 1983 | JP |
63-318934 | Dec 1988 | JP |
WO 9219145 | Nov 1992 | WO |
WO 9400178 | Jan 1994 | WO |
WO 9407445 | Apr 1994 | WO |
WO 9410948 | May 1994 | WO |
WO 9423794 | Oct 1994 | WO |
WO 9504385 | Feb 1995 | WO |
WO 9505869 | Mar 1995 | WO |
WO 9507664 | Mar 1995 | WO |
WO 9510326 | Apr 1995 | WO |
WO 9958070 | Nov 1999 | WO |
WO 0197897 | Dec 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20060135956 A1 | Jun 2006 | US |